FDA approves use of combo for hepatitis C in children
Schering-Plough obtained FDA clearance to market a regimen that combines Rebetol -- an antiviral drug -- with Pegintron -- a bioengineered version of an immune-system protein called interferon -- to treat hepatitis C in children ages 3 to 17. The two-drug therapy offers extended effectiveness with the aid of pegylation, a technology used in Pegintron that allows it to remain in the blood longer.
Winston-Salem Journal (N.C.) | 12/13
This story published in AABB SmartBrief on 12/15/2008
More from SmartBrief:
Study: Schering hepatitis drug induces rapid virologic response
Tuesday, November 3, 2009
Study identifies protein's important role in stem cell process
Thursday, August 27, 2009
Get stories like these delivered daily for FREE:
|
AABB SmartBrief
Designed specifically for the transfusion medicine and cellular therapy community, AABB SmartBrief is a FREE, daily e-mail newsletter. It provides a summary of the most important news in our field to members of AABB and beyond. To save time and stay smart, sign up today to receive AABB SmartBrief, free of charge. Learn more |
|